These findings uncover a previously unrecognized role for NSD3 in shaping tumor immunity and suggest that targeting UPR signaling could offer an effective strategy for treating NSD3-amplified, immunotherapy-resistant LUSC. Here, NSD3 is linked to neoplasm.